MedicalResearch.com Interview with:
Zobair Younossi, MD, MPH
Chairman, Department of Medicine, Inova Fairfax Hospital
Vice President for Research, Inova Health System
Falls Church, Virginia, USA
MedicalResearch: What are the main findings of the study?
Dr. Younossi: We conducted the analysis of
the patient reported outcomes (PROs) data that were systematically
collected during clinical trials of sofosbuvir-containing regimens. The
highlights of our findings are as follows:
- Patients with Hepatitis C (HCV) have a significant impairment of
their health related quality of life including those related to activity
and fatigue. Their work productivity is also impaired.
- Cirrhosis can add additional negative impact on some of these patient reported outcomes.
- During treatment, patients with cirrhosis who were treated with an
interferon-free sofosbuvir and ribavirin containing regimen did
experience mild decline in their patient related outcome scores.
However, this decline was similar for HCV patients with or without
- On the other hand, patients with cirrhosis who were treated with an
interferon-containing regimen showed a significant decline in
their patient reported outcomes scores compared to those with Hepatitis C and without cirrhosis.